Passa al contenuto
Merck
Tutte le immagini(1)

Documenti

SML2075

Sigma-Aldrich

Gimeracil

≥98% (HPLC)

Sinonimo/i:

5-Chloropyridine-2,4-diol, 5-chloro-4-hydroxypyridin-2(1H)-one, CDHP, Gimestat

Autenticatiper visualizzare i prezzi riservati alla tua organizzazione & contrattuali
Tutte le immagini(1)

About This Item

Formula empirica (notazione di Hill):
C5H4ClNO2
Numero CAS:
103766-25-2
Peso molecolare:
145.54
Numero MDL:
MFCD08458352
Codice UNSPSC:
12352200
NACRES:
NA.77

Saggio

≥98% (HPLC)

Forma fisica

powder

Colore

white to brown

Solubilità

DMSO: 2 mg/mL, clear

Temperatura di conservazione

−20°C

InChI

1S/C5H4ClNO2/c6-3-2-7-5(9)1-4(3)8/h1-2H,(H2,7,8,9)
ZPLQIPFOCGIIHV-UHFFFAOYSA-N

Azioni biochim/fisiol

Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an orally active inhibitor against dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine and the chemotherapeutic drug 5-fluorouracil (5FU). Gimeracil is shown to exhibit cancer-radiosensitizing efficacy in cultures in vitro (1 mM) and in mice in vivo (2.5-25 mg/kg, p.o.) in a DPYD-dependent manner via partial suppression of DNA repair by homologous recombination (HR).

Pittogrammi

Exclamation mark
GHS07

Avvertenze

Warning

Indicazioni di pericolo

H302

Classi di pericolo

Acute Tox. 4 Oral

Codice della classe di stoccaggio

11 - Combustible Solids

Classe di pericolosità dell'acqua (WGK)

WGK 3

Punto d’infiammabilità (°F)

Not applicable

Punto d’infiammabilità (°C)

Not applicable

Certificati d'analisi (COA)

Cerca il Certificati d'analisi (COA) digitando il numero di lotto/batch corrispondente. I numeri di lotto o di batch sono stampati sull'etichetta dei prodotti dopo la parola ‘Lotto’ o ‘Batch’.

Possiedi già questo prodotto?

I documenti relativi ai prodotti acquistati recentemente sono disponibili nell’Archivio dei documenti.

Visita l’Archivio dei documenti

Koh-Ichi Sakata et al.
Cancer science, 102(9), 1712-1716 (2011-06-15)
Gimeracil (5-chloro-2, 4-dihydroxypyridine) is an inhibitor of dihydropyrimidine dehydrogenase (DPYD), which degrades pyrimidine including 5-fluorouracil in the blood. Gimeracil was originally added to an oral fluoropyrimidine derivative S-1 to yield prolonged 5-fluorouracil concentrations in serum and tumor tissues. We have
T Wang et al.
Cancer radiotherapie : journal de la Societe francaise de radiotherapie oncologique, 20(3), 181-186 (2016-04-14)
This study evaluated the efficacy and safety of the combination drug tegafur, gimeracil, and oteracil potassium (S-1) concurrent with 3-dimensional conformal radiotherapy for newly diagnosed squamous cell carcinoma of the lung in elderly patients. Patients with pathologically or cytologically newly
Ryohei Nishiguchi et al.
BMJ case reports, 2016 (2016-12-10)
The most common histological classification of bile duct cancer is adenocarcinoma and squamous cell carcinoma (SCC) is relatively rare. We report a case of a 78-year-old man with SCC of the extrahepatic bile duct associated with metachronous para-aortic lymph node
Masakazu Fukushima et al.
Oncology reports, 24(5), 1307-1313 (2010-09-30)
Chemoradiotherapy is a useful treatment strategy in patients with locally advanced cancers. In particular, combination of 5-fluorouracil (5-FU) with X-ray irradiation is effective for the treatment of some types of gastrointestinal cancers. We investigated the antitumor effects of combination treatment
Keiji Koda et al.
Anticancer research, 36(10), 5325-5331 (2016-11-01)
It has not been elucidated whether the clinical efficacy of oral fluoropyrimidines for adjuvant chemotherapy of colorectal cancer varies with tumor biological characteristics. A multicenter randomized trial was performed comparing oral tegafur/gimeracil/oteracil (S-1) and uracil-tegafur/ leucovorin (UFT/LV) as adjuvant therapy

Il team dei nostri ricercatori vanta grande esperienza in tutte le aree della ricerca quali Life Science, scienza dei materiali, sintesi chimica, cromatografia, discipline analitiche, ecc..

Contatta l'Assistenza Tecnica.